In male mice undergoing cuprizone feeding, daily oral Laquinimod reduced demyelination scores compared with untreated mice. In another study under cuprizone feeding, Laquinimod significantly reduced the density of caspase-3-positive apoptotic cells in the corpus callosum compared with vehicle controls. In immunized DBA/1 mice, daily Laquinimod by oral gavage prevented EAE development compared with water vehicle. [2,3]
Laquinimod and Cuprizone-Induced Demyelination in Mice
Animal study · male C57BL/6J mice; cuprizone-induced demyelination [2]
Male mice with cuprizone-induced demyelination received Laquinimod orally each day from the beginning of cuprizone feeding. Demyelination scores were lower at both doses than in untreated mice.
Conditions shared by the study groups
- Route
- orally
- Treatment course
- daily; from the beginning of the cuprizone feeding; 6 weeks
- Laquinimod 5 and 25 mg/kg
- Model: male C57BL/6J mice; cuprizone-induced demyelination
- Reported limits: Not stated in the sentences used: vehicle. Removed after verification: value.
Methods and source locations
Compound reported in the paper: Laquinimod
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Test compounds and formulations (S1, S4); Materials and methods > Mice (S7); Materials and methods > Cuprizone treatment (S11); Materials and methods > Histopathology (S15); Results > LAQ inhibits cuprizone-induced demyelination in a dose-dependent manner (S85, S90); Fig. 2 legend (S142)
semi-quantitative scores for demyelination: semi-quantitative scores for demyelination; comparator: Control mice received vehicle. — Results > LAQ inhibits cuprizone-induced demyelination in a dose-dependent manner (S90); Fig. 2 legend (S142)
Laquinimod 5 and 25 mg/kg · Materials and methods > Test compounds and formulations (S1); Results > LAQ inhibits cuprizone-induced demyelination in a dose-dependent manner (S85, S90)
Laquinimod and EAE Development in Mice
Animal study · DBA/1 mice; n = 6/group [3]
DBA/1 mice received Laquinimod at 25 mg/kg by daily oral gavage starting on the day of immunization. Treatment prevented EAE development compared with water vehicle.
Conditions shared by the study groups
- Route
- oral gavage
- Treatment course
- daily; starting from the day of immunization
- Vehicle
- purified water
- Laquinimod 25 mg/kg
- Model: DBA/1 mice; n = 6/group
Methods and source locations
Compound reported in the paper: Laquinimod
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Laquinimod reverses EAE and inhibits pathogenic T cell immune responses (S3); Materials and Methods > EAE Induction (S57); Materials and Methods > Laquinimod treatment (S63); Figure 1 legend (S107, S114)
EAE disease course: EAE disease course; comparator: vehicle (water, n = 6/group) — Results > Laquinimod reverses EAE and inhibits pathogenic T cell immune responses (S3); Figure 1 legend (S114)
Laquinimod 25 mg/kg · Results > Laquinimod reverses EAE and inhibits pathogenic T cell immune responses (S3); Materials and Methods > Laquinimod treatment (S63); Figure 1 legend (S107)
Laquinimod and Apoptotic Cell Density in the Corpus Callosum
Animal study · male C57BL/6J mice; LAQ-treated mice (n = 10); controls (n = 10) [2]
Male mice undergoing cuprizone feeding received Laquinimod orally at 25 mg/kg daily from the beginning of feeding. The density of caspase-3-positive apoptotic cells in the corpus callosum was significantly lower in Laquinimod-treated mice than in vehicle controls.
Conditions shared by the study groups
- Route
- orally
- Treatment course
- daily; from the beginning of the cuprizone feeding; 1 week
- Laquinimod 25 mg/kg
- Model: male C57BL/6J mice; LAQ-treated mice (n = 10); controls (n = 10)
- Reported limits: Not stated in the sentences used: vehicle. Removed after verification: value.
Methods and source locations
Compound reported in the paper: Laquinimod
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Test compounds and formulations (S1, S4); Materials and methods > Mice (S7); Materials and methods > Histopathology (S16); Results > LAQ reduces cuprizone-induced apoptoses (S80, S84); Fig. 1 legend (S139)
density of caspase-3-positive apoptotic cells in the corpus callosum: density of caspase-3-positive apoptotic cells in the corpus callosum; comparator: Control mice received vehicle. — Results > LAQ reduces cuprizone-induced apoptoses (S84)
Laquinimod 25 mg/kg · Materials and methods > Test compounds and formulations (S1); Results > LAQ reduces cuprizone-induced apoptoses (S80, S84); Fig. 1 legend (S139)